Novasenta

About Novasenta

Novasenta is a pioneering biotech startup focused on discovering new therapeutic targets to develop innovative and effective treatments for cancer. The company operates at the intersection of biology and computation, leveraging advanced data mining and single-cell level analysis of high-quality human tumor samples. This approach accelerates the path from discovery to patient treatment.

Novasenta primarily serves pharmaceutical companies, research institutions, and healthcare providers who are looking for cutting-edge cancer therapies. The company is based in Pittsburgh, PA, a city known for its strong medical education, research, and technology sectors.

The business model of Novasenta revolves around its proprietary computational platforms, which are systematic, comprehensive, and scalable. These platforms facilitate active discovery dialogue between biologists and computational teams, speeding up the identification of novel cancer targets. Once potential targets are identified, they are validated using state-of-the-art in vitro (test tube experiments) and in vivo (animal models) assays, including CRISPR gene editing technology.

Novasenta makes money by partnering with pharmaceutical companies and research institutions that are interested in developing new cancer therapies. These partnerships often involve licensing agreements, research collaborations, and milestone-based payments.

In summary, Novasenta is a biotech startup that combines biology and computation to discover new cancer treatment targets, serving pharmaceutical companies and research institutions through a unique and scalable platform.